Reharvesting leukocytes from donors for a donor leukocyte infusion (DLI) is inconvenient and occasionally impossible in case of unrelated donors. It is well known that the effect of a growth factor-primed DLI is comparable to that of a nonprimed DLI. In total, 42 patients with hematologic malignancies and a high risk of relapse were allocated, on an intent-to-treat basis, a peripheral blood stem cell transplantation (PBSCT) from HLA-matched sibling donors, and then at the time of harvest, additional peripheral blood stem cells (PBSCs) were also reserved for a therapeutic primed DLI in case of relapse. In all, 12 patients who relapsed after allogeneic PBSCT were treated with mainly cytarabine-based chemotherapy followed by a cryopreserved PBSC infusion. The median dose of CD3 þ and CD34 þ cells for the primed DLIs was 1.43 Â 10 8 /kg and 4.75 Â 10 6 /kg, respectively. Six of the 12 relapsed patients exhibited a complete response after the primed DLI, plus their 1-year survival rate was 33%. The new development or progression of graft-versus-host disease after a primed DLI was observed in 50% of the patients. Overall, the survival at 1 year was 16.7%. Accordingly, the induction of a graftversus-leukemia effect through a primed DLI, using additional PBSCs reserved at the original time of harvest, would appear to be feasible for patients with relapsed hematologic malignancies. Furthermore, this approach is also more convenient for donors. The induction of a graft-versus-leukemia (GVL) effect by cytoreductive chemotherapy combined with a donor leukocyte infusion (DLI) is regarded as one of the main therapeutic options for relapsed hematologic malignancies after an allogeneic stem cell transplant (SCT).
growth factor-primed DLI The induction of a graft-versus-leukemia (GVL) effect by cytoreductive chemotherapy combined with a donor leukocyte infusion (DLI) is regarded as one of the main therapeutic options for relapsed hematologic malignancies after an allogeneic stem cell transplant (SCT). [1] [2] [3] [4] However, reharvesting leukocytes from donors in the case of relapse after an allogeneic SCT is inconvenient and occasionally impossible for unrelated donors. It is well known that the effect of a growth factor-primed DLI is comparable to that of a nonprimed DLI. [2] [3] [4] Moreover, there is an additional advantage that a growth factor-primed DLI can alleviate chemotherapy-induced pancytopenia. 3 As regards the feasibility of cryopreserving surplus peripheral blood stem cells (PBSCs), harvesting sufficient numbers of stem cells above the target cell dose from cytokine-mobilized healthy donors for transplantation in an allogeneic peripheral blood stem cell transplantation (PBSCT) is easier than a bone marrow transplantation (BMT). Accordingly, the current study evaluated the feasibility of a growth factorprimed DLI, using additional PBSCs reserved at the original time of harvest from HLA-matched sibling donors for an allogeneic PBSCT, in patients with hematologic malignancies with a high risk of relapse.
Design and methods

Study design
Patients with hematologic malignancies with a high risk of relapse were allocated, on an intent-to-treat basis, an allogeneic PBSCT from HLA-matched sibling donors, plus, at the time of harvest for transplantation, additional PBSCs were also reserved for a therapeutic DLI in the case of relapse. A high risk of relapse at transplantation was defined as the first complete remission (CR) with unfavorable cytogenetic abnormalities, 5 more than the first CR, advanced-phase chronic myelogenous leukemia (CML), and primary refractory or multiple relapsed malignancies. Patients who relapsed after their allogeneic PBSCT were treated with mainly cytarabine-based chemotherapy followed by a cryopreserved PBSC infusion. The additional PBSCs reserved at the time of transplantation were infused 10-14 days after the chemotherapy, when the nadir of the blood count was anticipated. DLI cell dose was determined according to disease subtype or aggressiveness. Briefly, infusion of over 0.5 Â 10 8 CD3 þ cells/kg was planned for the relapse of acute leukemia, myelodysplastic syndrome, or aggressive lymphoma. A lower CD3 þ cell dose was infused for CML. All patients were treated with the daily infusion of 400 mg of GM-CSF starting 1 day after the DLI until ANCX1000/ml. No GVHD prophylaxis was administrated in the post-DLI period. Grade I GVHD was generally not treated, yet grade II-IV GVHD was treated with corticosteroids and other immunosuppressive agents, including mycophenolate mofetil or tacrolimus. Acute and chronic GVHDs were classified according to standard criteria. 6, 7 PBSCT procedures Normal healthy donors gave consent to undergo largevolume (15 L) leukapheresis on day 5 after mobilization treatment with a growth factor, and to cryopreserve surplus PBSCs for the future use. Leukapheresis CD34 þ cells/kg was planned. Surplus cells over the target dose for successful transplantation were cryopreserved for future therapeutic growth factor-primed DLI in the case of relapse. Patients whose transplanted cell dose did not reach the target cell dose and were boosted with bone marrow cells from the same donor were excluded from this study. The PBSC products were infused fresh and unmanipulated. The extra harvested cells were divided into separate small bags without further processing and cryopreserved with dimethyl sulfoxide in a nitrogen tank. The PBSCs were mobilized with 10 mg/kg/day of GM-CSF (Sargramostim, Leucogen s , LGLS, Seoul, Korea) only (n ¼ 4 patients), a concurrent regimen (n ¼ 3 patients) of 5 mg/kg/day of G-CSF (Filgrastim, Leukokine s ; CJ, Co, Seoul, Korea), and 5 mg/kg/day of GM-CSF, or a sequential combination regimen (n ¼ 5 patients) 10 mg/kg/day of GM-CSF only for 3 days followed by 10 mg/kg/day of G-CSF only for 2-3 days. 8 Apheresis was repeated every morning until the target number of cells had been obtained. Prophylaxis against acute graft-versus-host disease (GVHD) consisted of methotrexate (MTX) and cyclosporin A (CyA). All patients were scheduled to receive 15 mg/m 2 of MTX on day 1 and 10 mg/m 2 of MTX on days 3, 6, and 11. CyA was administered intravenously at a dose of 2.5-5.0 mg/kg/day starting on the day before the PBSCT. Oral CyA (6 mg/kg/ day) was substituted for intravenous administration when it could be tolerated.
Assessment of response and evaluation of chimerism status
The effect of chemotherapy plus donor PBSC infusions was assessed by evaluating the blood and bone marrow morphology. A complete hematologic response was defined as a granulocyte count above 1 Â 10 9 /l in the peripheral blood, with the normal bone marrow showing less than 5% blast cells for at least 4 weeks. Bone marrow studies were performed 1, 3, and 6 months after therapy or more frequently if clinically indicated. The chimerism status, which was assessed by determining the variable number of tandem repeats (VNTRs) with a polymerase chain reaction analysis, was compared before and after the DLI.
Statistical analysis
The overall survival curves were plotted using the KaplanMeier method and compared using the log-rank test.
Results
Patient characteristics
A total of 42 patients with hematologic malignancies and a high risk of relapse were enrolled in the current study. Among the enrolled patients, 12 patients (28.6%) relapsed after an allogeneic PBSCT. The patients' characteristics are summarized in Table 1 (Table 2) . After the allogeneic PBSCT, 11 out of 12 patients were in CR, and one patient with non-Hodgkin's lymphoma (NHL) did not achieve a CR. Eight patients developed grade I-III acute GVHD after the PBSCT, and five out of 10 patients assessed for chronic GVHD developed chronic GVHD. The time from the PBSCT to the relapse ranged from 56 to 278 days (median, 143 days).
Cytoreductive therapy and primed DLI
For the cytoreduction before the DLI, 11 patients received cytarabine at 3 g/m 2 /day intravenously for 3 days and one patient with NHL received CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) therapy. The DLIs were performed between days 14 and 39 after the relapse. 6 /kg (range, 0.14-9.20 Â 10 6 /kg), respectively ( Table 2 ). The viability of cells after thawing was median 88% (range, 83-92%).
Disease response and survival
The clinical outcomes are summarized in Table 3 . Six out of the 12 relapsed patients exhibited a CR after the PBSC infusion, plus their 1-year survival rate was 33%. Of these (Figure 1 ).
Primed-DLI toxicity
The new development or progression of GVHD after the DLI was observed in six (50%) patients, which was also associated with a better survival (group with GVHD vs without GVHD; 1-year overall survival, 33.3 vs 0%) (Figure 2 ). Among these patients, four (66.6%) patients developed chronic GVHD (three extensive, one limited). The median recovery time until 4500 ANC/ml after the DLI was 5.5 days (range, 0-27 days). Fever developed in 66.7% after the DLI, and the median febrile duration was 6 days (range, 3-11 days). One (8.3%) patient with AML M7 died from bacterial pneumonia 13 days after the DLI.
Chimerism status
Of the 11 patients evaluated for their chimerism status by VNTR at the time of relapse, 10 showed mixed or full recipient chimerism, while one patient with NHL (UPN 9) showed full donor chimerism. Of the 10 patients who showed mixed or recipient chimerism, five (50.0%) patients converted to donor chimerism after chemotherapy plus a primed DLI, and all developed GVHD.
Discussion
In patients receiving an allogeneic SCT for early leukemia, the relapse rates vary within a range of o10-40%. However, patients with a more advanced form of the disease have a higher relapse rate approaching 50-70%, with T-cell depletion or the absence of GVHD being important prognostic factors for relapse. [10] [11] [12] The various options in the case of relapse include aggressive chemotherapy, a second SCT, DLI, or a combination; however, the best management is still uncertain. The response to conventional chemotherapy is generally poor, and longterm survivors are rare in relapsed patients after an allogeneic SCT. A second allogeneic SCT is only recommended in late relapses, because patients relapsing within the first year of an SCT experience the worst outcome. 13, 14 Encouraging results have been obtained with a DLI for some specific diseases, [15] [16] [17] as the procedure appears to promote the expansion of donor hematopoiesis by a GVL effect aimed at destroying the leukemic clone. The probability of response is high in chronic myelogenous leukemia, while the results are poor in acute leukemia. 16, 17 Since Szer et al 1 reported that the addition of donor leukocytes to salvage chemotherapy might produce durable remissions by inducing the GVL effect in patients with AML relapsing after an SCT, several studies have evaluated the effect and safety of chemotherapy plus a DLI. [2] [3] [4] In the current study, cytarabine-based chemotherapy plus PBSC infusions for the treatment of relapsed hematologic malignancies after an allogeneic PBSCT produced a CR rate of 50% (6/12), 1-year survival rate of 16.7%, and treatment-related mortality rate of 8.3%. These results are similar to those reported in previous studies 3, 4 in terms of the CR rate and survival. Several reports have suggested that the GVL effect is increased in an allogeneic PBSCT than in an allogeneic BMT. [18] [19] [20] As such, this raises the hypothesis that leukemic clones surviving an allogeneic PBSCT may be more resistant to the GVL effect induced by a DLI than after an allogeneic BMT. If so, the survival rate of 16.7% in the current trial should not be directly compared to rates in other studies on relapse after an allogeneic BMT. Based on this hypothesis, a protocol including an early DLI or prophylactic DLI on an intentto-treat basis could be considered for patients with a high risk of relapse after an allogeneic PBSCT. However, a more extensive study will be needed to clarify the role of a DLI in hematologic patients relapsed after an allogeneic PBSCT. Recently, PBSCs mobilized by hematopoietic growth factors instead of nonprimed DLIs for the treatment of relapsed leukemia are being increasingly used to mitigate chemotherapy-induced cytopenia. 3, 4, 21, 22 Murine and human studies have suggested that G-CSF administration results in the polarization of T cells toward TH2 cells. [23] [24] [25] Although murine studies suggest that such polarization can lead to a GVL effect without GVHD, 24, 25 whether this results in more or less GVL or GVHD activity is still uncertain. However, Alessnandrino et al 3 suggested that a PBSC infusion assists in the prompt re-establishment of normal donor hematopoiesis, thereby avoiding the prolonged cytopenia observed after a DLI. 15, 16 The current study also showed that the median recovery time until 4500 ANC/ml after a primed DLI was 5.5 days (range, 0-27 days), which seemed to be a relatively short duration.
Leukapheresis with or without CSF administration from donors for a primed or nonprimed DLI after transplantation is inconvenient for donors. Therefore, the main purpose of the current study was to evaluate the feasibility of a therapeutic growth factor-primed DLI, using extra cells reserved at the original time of harvest for transplantation, in patients with a high risk of relapse on an intentto-treat basis. Thus, in the current study, 12 patients (28.6%) who relapsed after transplantation were treated with cryopreserved PBSCs without the need to reharvest additional leukocytes from the donors. The strategy of collecting a sufficient number of cells at the time of harvest for transplantation via an allogeneic PBSCT enables a prophylactic or therapeutic growth factor-primed DLI to be prepared in the case of high-risk hematologic malignancies without the need to harvest additional leukocytes from the original donors.
Consequently, the induction of a GVL effect through chemotherapy, combined with a growth factor-primed PBSC infusion using additional cells reserved at the original time of harvest for transplantation, would appear to be a feasible strategy for patients with relapsed hematologic malignancies. Furthermore, this approach is also more convenient for donors.
